Schedule 13D ownership disclosure

CASI PHARMACEUTICALS INC

Ordinary Shares · CUSIP: G1933S101

Event date: 2025-06-16

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • WEI-WU HE, Ph.D.Reported CIK 0001542073

    Shares: 3,735,535.00 · Class: 23.8%

  • HUIYING MEMORIAL FOUNDATION

    Shares: 407,644.00 · Class: 2.6%

  • EMERGING TECHNOLOGY PARTNERS, LLC

    Shares: 1,097,341.00 · Class: 7.1%

  • ETP Global Fund L.P.

    Shares: 753,234.00 · Class: 4.9%

  • ETP BIOHEALTH III FUND , L.P.

    Shares: 300,000.00 · Class: 1.9%

  • HE Family GRAT

    Shares: 100,000.00 · Class: 0.6%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-061185
Form type
SCHEDULE 13D/A
Filer
CASI Pharmaceuticals, Inc.
CIK
CIK 1962738
Filed
Jun 20, 2025
Reporting period
Jun 16, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub